MEI Pharma Inc. (MEIP)

2.73
NASDAQ : Health Technology
Prev Close 2.78
Day Low/High 2.68 / 2.89
52 Wk Low/High 1.82 / 5.14
Avg Volume 258.50K
Exchange NASDAQ
Shares Outstanding 71.11M
Market Cap 197.70M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

MEI Pharma Reports First Quarter Fiscal Year 2019 Results And Operational Highlights

MEI Pharma Reports First Quarter Fiscal Year 2019 Results And Operational Highlights

-- MEI on Track to Initiate ME-401 Phase 2 Accelerated Approval Study Around Year-End --

MEI Pharma To Present At Stifel 2018 Healthcare Conference

MEI Pharma To Present At Stifel 2018 Healthcare Conference

SAN DIEGO, Nov. 6, 2018 /PRNewswire/ -- MEI Pharma, Inc.

MEI Pharma And Kyowa Hakko Kirin Announce License Agreement To Develop And Commercialize ME-401 In Japan

MEI Pharma And Kyowa Hakko Kirin Announce License Agreement To Develop And Commercialize ME-401 In Japan

MEI to Receive $10 Million Upfront Payment, Plus Milestones and Tiered Royalty Payments

MEI Pharma Reports Fiscal Year 2018 Results And Operational Highlights

MEI Pharma Reports Fiscal Year 2018 Results And Operational Highlights

-Fiscal Year 2018 Highlighted by Progress Across All Four Clinical-stage Oncology Candidates; ME-401 Accelerated Approval Study to Start by Year-end 2018-

MEI Pharma To Present At Wells Fargo Securities 2018 Healthcare Conference

MEI Pharma To Present At Wells Fargo Securities 2018 Healthcare Conference

SAN DIEGO, Aug. 29, 2018 /PRNewswire/ -- MEI Pharma, Inc.

MEI Pharma To Release 2018 Fiscal Year End Financial Results And Provide Corporate Update On August 30, 2018

MEI Pharma To Release 2018 Fiscal Year End Financial Results And Provide Corporate Update On August 30, 2018

SAN DIEGO, Aug. 23, 2018 /PRNewswire/ -- MEI Pharma, Inc.

MEI Pharma Reaches Analyst Target Price

In recent trading, shares of MEI Pharma Inc have crossed above the average analyst 12-month target price of $3.17, changing hands for $3.30/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Interesting MEIP Call Options For December 16th

Interesting MEIP Call Options For December 16th

Investors in MEI Pharma Inc saw new options begin trading this week, for the December 16th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 136 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

MEI Pharma (MEIP) Stock Soars on Leukemia Treatment's Phase 2 Trial Results

MEI Pharma (MEIP) Stock Soars on Leukemia Treatment's Phase 2 Trial Results

MEI Pharma (MEIP) stock is surging in early-morning trading on Monday, after the oncology company announced positive results from its leukemia treatment's Phase II trial.

MEI Pharma (MEIP) Stock Rises Today Following Monday's Sharp Decline

MEI Pharma (MEIP) Stock Rises Today Following Monday's Sharp Decline

Shares of MEI Pharma (MEIP) were up in late morning trading Tuesday as investors swooped into the stock following its significant decline on Monday.

MEI Pharma (MEIP) Stock Plummets to 52-Week Low After Cancer Drug Trial Results

MEI Pharma (MEIP) Stock Plummets to 52-Week Low After Cancer Drug Trial Results

Shares of MEI Pharma (MEIP) plunged to a one-year low on Monday after the company announced its cancer drug Pracinostat failed to meet its main goal in a mid-stage trial.

Machines Drive the Action

Today had nothing to do with fundamentals.

Buyers Get Back to Big-Caps

Market shows some love to overlooked groups.

Looks Like Pessimism Is on the Rise

But there's aggressive capital that wants to be spent.

First Week of April 17th Options Trading For MEI Pharma (MEIP)

First Week of April 17th Options Trading For MEI Pharma (MEIP)

Investors in MEI Pharma Inc saw new options become available this week, for the April 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MEIP options chain for the new April 17th contracts and identified one put and one call contract of particular interest.

This Greece Charade Isn't Ending

But we can enjoy another dozen Greece-is-saved rallies.

4 Biotech Stocks Under $10 Triggering Breakouts: Amarin, Exelixis and More

4 Biotech Stocks Under $10 Triggering Breakouts: Amarin, Exelixis and More

Keep these under-$10 biotech stocks on your breakout trading radar.

The Fed Is Still the Bulls' Best Friend

But it's losing some of its luster.

5 Under-$10 Health Care Stocks Setting Up to Trade Higher

5 Under-$10 Health Care Stocks Setting Up to Trade Higher

These setups often produce monster moves higher in very short time frames.

Oversold Conditions For MEI Pharma (MEIP)

Oversold Conditions For MEI Pharma (MEIP)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

3 Under-$10 Health Care Stocks Triggering Breakout Trades

3 Under-$10 Health Care Stocks Triggering Breakout Trades

Keep these health care stocks under $10 on your breakout trading radar.

5 Breakout Stocks Under $10 Set to Soar

5 Breakout Stocks Under $10 Set to Soar

These under-$10 stocks look ready to break out and trade higher from current levels.

3 Biotech Stocks Under $10 to Trade for Breakouts

3 Biotech Stocks Under $10 to Trade for Breakouts

These under-$10 biotech stocks are within range of triggering breakout trades.

4 Biotech Stocks Under $10 to Watch for Breakout Trades

4 Biotech Stocks Under $10 to Watch for Breakout Trades

These under-$10 biotech stocks are within range of triggering breakout trades.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks are within range of triggering breakout trades.

TheStreet Quant Rating: D (Sell)